Clinically available drugs targeting CSF1 or CSF1R include pexidartinib, which repolarizes M2 macrophages [54] and has demonstrated safety and activity in a phase 3 trial [55] resulting in the first available systemic therapy available for tenosynovial giant cell tumors. The gene discussed is CSF1; the disease is giant cell tumor.